esophageal cancer
Conditions
Interventions
None listed
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Histologic evidence of invasive adenocarcinoma or squamous cell cancer of the esophagus • Patient eligible for trimodality treatment (chemoradiotherapy and surgery) or definitive chemoradiotherapy • T3N0M0 or T1-4N1-3M0. Patients with M1 disease solely on the basis of supraclavicular metastasis and not a junction tumor as primary are eligible. (AJCC 7th edition) • WHO performance status = 18 years • Written informed consent before endoscopy or EUS
Exclusion criteria
Exclusion criteria: • Prior treatment with thoracic surgery or thoracic radiotherapy • Pregnancy • Severe cardiopulmonary restriction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint of this study is to quantify motion of the esophageal tumor over the course of chemoradiation. Fiducial markers placed in the esophageal wall will be taken as surrogate position of the tumor. By matching the markers on the reference scan the motion variables can be obtained. These different variables are necessary to calculate the corresponding PTV margin. These motion variables are; • Bony anatomy setup error, this is defined as the discordance between the patient*s position from baseline treatment planning position by external fiducial markers and the bony setup correction deriving from the CBCT • Peak-to-peak amplitude of the GTV/CTV by breathing motion • Baseline shifts (inter and intra fraction) • Inter-fraction motion; defined as the motion in between 2 radiation fractions • Intra-fraction motion; defined as the motion occurring within the time period of a single daily fraction | — |
Secondary
| Measure | Time frame |
|---|---|
| • Peak to peak amplitudes of mid-thoracic versus distal/ GE-junctional tumors • Correlation of tumor response on FDG-PET scan (SUV decline) and DCE-MRI (change in Ktrans) with pathological response for trimodality patients • Correlation of combined PET and DCE-MRI results with pathological response for trimodality patients • SUVmax of the primary tumor on 3D versus 4D PET • DCE*MRI of the esophagus for treatment planning and response monitoring •* Ease of insertion, migration and visibility of different fiducial markers | — |
Countries
Netherlands
Outcome results
None listed